Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Blood Cancer Clinical Trials

A listing of Blood Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (253) clinical trials

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

Phase

The purpose of this Study is to find out if the study drug ruxolitinib (“Study Drug” or ruxolitinib) is safe and effective compared to anagrelide hydrochloride (also known as Agrylin® or anagrelide), in people who have Essential Thrombocythemia (ET) and are resistant to or intolerant of Hydroxyurea. 

Phase

The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.   This is an open-label Phase 2 study with 2 cohorts: Cohort A: Itacitinib plus ruxolitinib  Drug: Itacitinib self-administered orally once daily at the   protocol-defined ...

Phase

Pedometer Activity Monitoring After ASCT

Patient-reported outcome measures (PROMs) Cancer patients experience significant physical and psychosocial consequences of cancer and treatment which affect quality of life (QoL). These consequences may be under-recognized and under-treated in oncology practice, resulting in greater morbidity that is costly to patients and the health system. Patient-reported outcome measures (PROMs) are ...

Phase

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma ...

Phase

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

PRIMARY OBJECTIVES: I. To assess the efficacy of the combination of ibrutinib and obinutuzumab in chemotherapy naive patients with indolent lymphomas. SECONDARY OBJECTIVES: I. To assess progression free survival rates and overall survival rates in indolent lymphomas. II. To assess safety and tolerability of the combination. III. To evaluate response ...

Phase

A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

Primary Objective: To assess 2 year probability of OS in high risk patients undergoing a myeloablative 2 step HSCT utilizing strategies to decrease relapse. Secondary Objective: To assess relapse incidence at 2 years post-HSCT of patients undergoing treatment on this protocol. To assess regimen related toxicity and GVHD incidence at ...

Phase

Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide

An open label, single-arm, single-center study to evaluate the safety, efficacy and feasibility of haplo-SCT as an alternative donor source for patients who lack a matched sibling/unrelated donor options. The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone ...

Phase

Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation

PATIENT ENROLMENT. It is expected that about 15 patients / year will be enrolled in this phase I-II protocol. Patient selection will be based on the following criteria: Eligibility Criteria: Any patient with one of the following lympho or myeloproliferative malignancies or syndromes in whom allogeneic NST is warranted. Patients ...

Phase

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic HSCT using a unique non-myeloablative preparative regimen, TLI/ATG, ...

Phase